Literature DB >> 24716595

Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis.

Yoshiro Horai1, Tomohiro Koga, Keita Fujikawa, Ayuko Takatani, Ayako Nishino, Yoshikazu Nakashima, Takahisa Suzuki, Shin-ya Kawashiri, Naoki Iwamoto, Kunihiro Ichinose, Mami Tamai, Hideki Nakamura, Hiroaki Ida, Tomoyuki Kakugawa, Noriho Sakamoto, Yuji Ishimatsu, Hiroshi Mukae, Yasuhito Hamaguchi, Manabu Fujimoto, Masataka Kuwana, Tomoki Origuchi, Shigeru Kohno, Atsushi Kawakami.   

Abstract

OBJECTIVE: We have tried to clarify the clinical importance of the measurement of serum type-I interferon (IFN) in patients with anti-melanoma differentiation-associated gene 5 Ab (MDA5 Ab)-positive dermatomyositis (DM).
METHODS: We studied 30 patients with DM: 10 were anti-MDA5 Ab-positive and 20 were anti-MDA5 Ab-negative. At each patient's initial visit, serum IFN-α, IFN-β, interleukin 18 (IL-18), ferritin, and the titer of anti-MDA5 Ab were measured using enzyme-linked immunosorbent assays (ELISAs). The associations between the IFNs and with the other variables were examined.
RESULTS: Rapidly progressive interstitial lung disease (RPILD) was confirmed in 10 patients, most of whom were complicated in the anti-MDA5 Ab-positive DM patients. The presence of clinically amyopathic dermatomyositis (CADM) as well as the serum concentrations of IFN-α and ferritin was significantly higher in the anti-MDA5 Ab-positive DM patients. Serum concentration of IL-18 did not differ between anti-MDA5 Ab-positive and anti-MDA5 Ab-negative groups; however, a positive correlation was found between IFN-α and IL-18 in the anti-MDA5 Ab-positive DM patients (r = 0.8139, p = 0.0146).
CONCLUSION: Serum IFN-α can be used as a useful biomarker in patients with anti-MDA5 Ab-positive DM, which may reflect the presence of RPILD.

Entities:  

Keywords:  CADM; Ferritin; IFN-α; RPILD; anti-MDA5 antibody

Mesh:

Substances:

Year:  2014        PMID: 24716595     DOI: 10.3109/14397595.2014.900843

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  23 in total

Review 1.  Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis.

Authors:  Wanlong Wu; Li Guo; Yakai Fu; Kaiwen Wang; Danting Zhang; Wenwen Xu; Zhiwei Chen; Shuang Ye
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-06       Impact factor: 8.667

Review 2.  MDA5 autoantibody-another indicator of clinical diversity in dermatomyositis.

Authors:  Richard D Sontheimer
Journal:  Ann Transl Med       Date:  2017-04

3.  A New Predictive Model for the Prognosis of MDA5+ DM-ILD.

Authors:  Qian Niu; Li-Qin Zhao; Wan-Li Ma; Liang Xiong; Xiao-Rong Wang; Xin-Liang He; Fan Yu
Journal:  Front Med (Lausanne)       Date:  2022-06-15

4.  Chemokine profiles of interstitial pneumonia in patients with dermatomyositis: a case control study.

Authors:  Katsuhiro Oda; Takuya Kotani; Tohru Takeuchi; Takaaki Ishida; Takeshi Shoda; Kentaro Isoda; Shuzo Yoshida; Yasuichiro Nishimura; Shigeki Makino
Journal:  Sci Rep       Date:  2017-05-09       Impact factor: 4.379

5.  Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis.

Authors:  Liubing Li; Qian Wang; Funing Yang; Chanyuan Wu; Si Chen; Xiaoting Wen; Chenxi Liu; Yongzhe Li
Journal:  Oncotarget       Date:  2017-04-18

6.  Clinically Amyopathic Dermatomyositis with Interstitial Pneumonia That Was Successfully Treated with Plasma Exchange.

Authors:  Mizuki Yagishita; Yuya Kondo; Toshihiko Terasaki; Mayu Terasaki; Masaru Shimizu; Fumika Honda; Ayako Oyama; Hiroyuki Takahashi; Masahiro Yokosawa; Hiromitsu Asashima; Shinya Hagiwara; Hiroto Tsuboi; Isao Matsumoto; Takayuki Sumida
Journal:  Intern Med       Date:  2018-02-28       Impact factor: 1.271

Review 7.  MDA5-positive dermatomyositis: an uncommon entity in Europe with variable clinical presentations.

Authors:  Anna Radice; Boaz Palterer; Paola Parronchi; Francesco Liotta; Cristina Scaletti
Journal:  Clin Mol Allergy       Date:  2015-11-09

8.  Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease.

Authors:  Liubing Li; Qian Wang; Xiaoting Wen; Chenxi Liu; Chanyuan Wu; Funing Yang; Xiaofeng Zeng; Yongzhe Li
Journal:  Oncotarget       Date:  2017-07-06

9.  Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis.

Authors:  Yuichi Ishikawa; Shigeru Iwata; Kentaro Hanami; Aya Nawata; Mingzeng Zhang; Kaoru Yamagata; Shintaro Hirata; Kei Sakata; Yasuyuki Todoroki; Kazuhisa Nakano; Shingo Nakayamada; Minoru Satoh; Yoshiya Tanaka
Journal:  Arthritis Res Ther       Date:  2018-10-26       Impact factor: 5.156

10.  Rheumatoid Arthritis Complicated with Anti-melanoma Differentiation-associated Gene 5 Antibody-positive Interstitial Pneumonia.

Authors:  Haruki Matsumoto; Shuzo Sato; Yuya Fujita; Makiko Yashiro-Furuya; Naoki Matsuoka; Tomoyuki Asano; Hiroko Kobayashi; Hiroshi Watanabe; Kiyoshi Migita
Journal:  Intern Med       Date:  2018-10-17       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.